Dermaliq

Dermaliq Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company founded in 2021 as a spin-off from Novaliq GmbH to advance novel topical drug therapies in dermatology. The company's proprietary hyliQ™ technology platform enables cutaneous drug delivery with superior bioavailability compared to conventional topical formulations. Dermaliq's pipeline includes DLQ01 (topical androgenetic alopecia treatment targeting PGE2 receptors), DLQ02 (calcineurin inhibitor for plaque psoriasis), and DLQ03 (broad-spectrum topical antibiotic for skin and soft tissue infections). The company raised a USD 15 million Series A in January 2022 co-led by 3E Bioventures Capital and Beijing Whale Technology. Dermaliq is incorporated in Wilmington, Delaware and led by CEO Dr. Frank Löscher.